NEXLETOL
Peakbempedoic acid
NDAORALTABLET
Approved
Feb 2020
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
15
Data completeness
6/8 — Strong
NEXLETOL (bempedoic acid) is adenosine triphosphate-citrate lyase inhibitors [moa]. Approved for hypercholesterolemia, mixed dyslipidemia. First approved in 2020.
Drug data last refreshed Yesterday · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NEXLETOL (bempedoic acid) is an oral tablet approved in February 2020 that works as an adenosine triphosphate-citrate lyase (ACL) inhibitor, a novel mechanism for lowering cholesterol. It is indicated for patients with hypercholesterolemia and represents a non-statin option for lipid management. The product addresses an unmet need in patients who are statin-intolerant or require additional LDL-C reduction beyond current therapies.
$0.0BPart D
14.1 years to LOEMechanism of Action
Adenosine Triphosphate-Citrate Lyase Inhibitors
Pharmacologic Class:
Adenosine Triphosphate-Citrate Lyase Inhibitor
Indications (2)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.